|Videos|August 22, 2022

Study shows potential of ctDNA as biomarker for immunotherapy response in GU cancers

Albert Jang, MD, discusses the promise of using ctDNA to determine whether patients with advanced genitourinary cancers are responding to immune checkpoint inhibitors.

Albert Jang, MD, a 3rd-year internal resident physician at Tulane University, discusses the study, “Prospective Evaluation Of Circulating Tumor Dna (ctDNA) in Detecting Early Progression on Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Cancers,” which he shared at the 2022 AUA Annual Meeting.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!

Related Content

Latest CME

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment
Virtual Event

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

February 23, 2026

View more
Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD
Video

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

View more